Huateng Pharma Provides Orlistat Intermediates CAS NO 104801-96-9 Large Scale Services

Creative Biogene: A Premier Partner in the Exploration of Pathogenesis of Mitochondrial-Associated Diseases

Creative Biogene has become the premier partner to cooperate in the exploration of the pathogenesis of mitochondrial-associated diseases.

Abzena, Alira Health and Oncodesign launch DRIVETM-Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation

Pronalyse Launches Antibody Drug Conjugates (ADCs) Characterization Service for Drug Discovery

Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs.

Lipidomics Bioinformation Analysis Now Available by Creative Proteomics’s Lipidomics Platform

As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, revealing the physiological mechanism of their changes.

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Microbial Metabolomics Solutions

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. With deep industry and business process expertise and a good reputation in providing contract services specialized for metabolomics, Creative Proteomics Metabolomics announced the launch of microbial metabolomics service to promote a comprehensive understanding of microbial physiology.

PhenoTips pledges 1% of their equity to The Upside Foundation in support of CHEO Foundation, SickKids Foundations, Canadian Organization of Rare Disorders

PhenoTips, producer of the leading software solution for medical genetics, is proud to announce the pledge of 1% of their equity to The Upside Foundation of Canada in support of CHEO Foundation, SickKids Foundation, and the Canadian Organization of Rare Disorders (CORD).

ERGOMED announces launch of its Rare Disease Innovation Center™

ERGOMED announces launch of its Rare Disease Innovation Center™ Rare Disease Innovation Center to provide strategic guidance and tailored innovative solutions to sponsors focused on rare disease drug development Raleigh, North Carolina, February 28, 2022 – ERGOMED plc (LSE: ERGO) a leading Clinical Research Organization focused on rare disease drug development today announced the establishment of its Rare Disease Innovation Center.

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center Collaboration will provide sponsors with access to industry-leading technology and expertise to optimise rare disease drug development and tackle unmet medical need. Bracknell, UK: 28 February 2022 – mdgroup, the leading global provider of personalised clinical study services and technologies, has been selected to provide patient support services to Ergomed’s Rare Disease Innovation Centre.

Rho Awarded NIH-NIAID Contract to Support Clinical Research in Autoimmune Diseases

Research Triangle Park, NC – February 28, 2022 – Rho, a global, full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it has been named the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) for the National Institute of Allergy and Infectious Diseases. As the AD-SCCC, Rho will provide a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This project has been funded $8.3 million in the first year with Federal funds from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93022C00003. This award has the potential to provide a total of over $49 million to the AD-SCCC over the next five years.

AccessDx PGx Profile Drives Greater Precision in Medication Optimization

AccessDx Laboratory, a global provider of advanced laboratory diagnostics solutions, has introduced an expanded pharmacogenomics (PGx) test that improves the quality, availability and actionability of drug-gene insights within the clinical workflow. The AccessDx PGx Profile is designed to help providers identify potential risks for adverse drug reactions or reduced medication efficacy.

VERICHEM NOW OFFERS MATRIX PLUS ™ CHEMISTRY REFERENCE MATERIALS FOR CALIBRATION VERIFICATION APPLICATIONS

VERICHEM offers clinical laboratories their liquid stable and ready-to-use MATRIX PLUS™ Chemistry Reference Materials which are expressly designed for the calibration and calibration verification of chemistry assays and to support overall system QC and CLIA compliance.

ClinOne Names Clinical Research Technology Leader Andrea Valente Chief Executive Officer

Valente brings strategic leadership, industry, product and operational experience needed at a pivotal moment in the company’s exponential growth

CD Formulation Offers Customized Synthesis to Meet the Demand for Lipid Excipients

As a New York-based CRO company, CD Formulation has keenly observed that the demand for tailored pharmaceutical excipients is on the rise, especially over the past decade, as each formulation project may need unique excipients. In response to such a market trend, the management of CD Formulation earlier this month announces to offer customized synthesis for lipid excipients, which are used in lipid-based dosage forms for the enhancement of drug absorption or delivery.

Nanomaterial News Update: Alfa Chemistry Upgrades Its Nanoprism Product Line

Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software

Optibrium Ltd, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. More than 160 organisations currently use StarDrop, including many of the world’s leading pharmaceutical companies. The new release introduces Inspyra™, a module that dynamically learns from chemists’ expert knowledge and feedback to guide automated compound design methods, creating a powerful ‘augmented intelligence’ to accelerate the discovery of high-quality drug candidates.

Digital Health Companies Orbita and OnCall Health Choose Lyniate for Reliable Interoperability

Domainex expands analytical chemistry capabilities with over £1M worth of new Waters equipment

Cambridge, United Kingdom, 3rd March 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, announces that it has purchased over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The new equipment will allow Domainex to increase its capacity and throughput, supporting its ongoing growth.

WuXi STA Passes the First EMA Drug Product Pre-Approval Inspection at its Wuxi City Site

Qlucore receives second commercial order for new solution

The Swedish Nasdaq First North listed software company Qlucore, focused on cancer diagnostics, has signed an agreement with the Molecular Oncohematology Research Group at the Department of Pathology and Experimental Cancer Research at Semmelweis University. The group will use Qlucore’s software to improve diagnostics of acute lymphoblastic leukemia (ALL) and collaborate on a new classification model using the Trusight Pan-Cancer panel.